TMOHealthcare · Diagnostics & ResearchThe 27 Wall Street analysts covering Thermo Fisher Scientific, Inc. hold a median 12-month price target of $690 — -0.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 14 Oct 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Thermo Fisher Scientific, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (96): The share price has been relatively steady.
Accruals (35): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TMO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −0.9% from it.
Of the 20 most recent actions, 8 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | Morgan Stanley | Maintains | Overweight | $650 → $730 |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $675 → $760 |
| 7 Oct 2026 | Barclays | Maintains | Overweight | $650 → $750 |
| 9 Sept 2026 | UBS | Assumes | Buy | $540 → $730 |
| 3 Sept 2026 | CLSA | Initiates | Outperform | — |
| 3 Sept 2026 | CLSA | Initiates | Outperform | $748 |
| 27 July 2026 | Morgan Stanley | Maintains | Overweight | $620 → $650 |
| 27 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 27 July 2026 | Piper Sandler | Maintains | Neutral | — |
| 27 July 2026 | Piper Sandler | Maintains | Neutral | $510 → $600 |
| 24 July 2026 | Barclays | Maintains | Overweight | — |
| 24 July 2026 | Barclays | Maintains | Overweight | $625 → $650 |
| 24 July 2026 | RBC Capital | Maintains | Sector Perform | $490 → $580 |
| 24 July 2026 | RBC Capital | Maintains | Sector Perform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $575 → $570 |
| 26 June 2026 | Bernstein | Reinstates | Market Perform | $520 |
| 11 June 2026 | Piper Sandler | Initiates | Neutral | — |
| 3 June 2026 | HSBC | Downgrade | Hold | — |
| 2 June 2026 | Wolfe Research | Assumes | Outperform | $535 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TMO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Oct 2026, Thermo Fisher Scientific, Inc. returned +32.4% against +16.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 21% of US stocks
Cheaper than 23% of US stocks
Cheaper than 21% of US stocks
Cheaper than 11% of US stocks
Higher than 53% of US stocks
Higher than 44% of US stocks
Higher than 50% of US stocks
Higher than 77% of US stocks
Higher than 78% of US stocks
Higher than 72% of US stocks
Higher than 77% of US stocks
Higher than 64% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Thermo Fisher Scientific, Inc. has a market value of $248.9B and an enterprise value of $287.5B.
Revenue in the twelve months to 30 June 2026: $46.3B. The latest quarter grew 10.5% year on year.
Net income over the same four quarters: $7.0B, a 15.1% net margin.
Diluted earnings per share, trailing twelve months: $18.59.
Free cash flow in the twelve months to 30 June 2026: $7.3B.
Thermo Fisher Scientific, Inc. spent $5.0B on share buybacks and $662.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 36.2×; forward P/E: 24.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.28%, paying out 10% of earnings.
Thermo Fisher Scientific, Inc. employs 125,000 people — $371K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Thermo Fisher Scientific, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
On CNBC’s “Halftime Report Final Trades,” Stephen Weiss picked the U.S. 10 Year Treasury. The excerpt does not say that he selected Thermo Fisher Scientific.
Why it matters — The headline mentions Thermo Fisher, but the excerpt provides no company-specific news or commentary for TMO watchers.
Zacks Investment Research says Thermo Fisher is scheduled to report next week, with Wall Street expecting earnings growth. The excerpt says the company lacks the combination of two key ingredients for a likely earnings beat.
Why it matters — TMO watchers may note the upcoming report and the excerpt’s caution that a likely earnings beat is not supported by those indicators.
Danaher announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. The announcement marks a development in life science automation, though trading barely moved on the news date.
Why it matters — A TMO watcher may note the development as an example of AI-driven automation in the life sciences sector.
Thermo Fisher is preparing to report Q3 earnings, with revenue and EPS growth expected. The excerpt cites strong bioproduction demand, product innovations and clinical research strength.
Why it matters — The earnings report will provide an update on performance in areas identified as supporting expected growth.
Thermo Fisher Scientific (TMO) was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects.
Why it matters — The upgrade signals a more optimistic assessment of TMO’s earnings outlook.
The 27 Wall Street analysts covering Thermo Fisher Scientific, Inc. have a median 12-month price target of $690, with estimates ranging from $560 to $800. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 27 analysts covering Thermo Fisher Scientific, Inc., 23 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Thermo Fisher Scientific, Inc. 84 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Thermo Fisher Scientific, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).
No one can know that. What the data says: the median 12-month target from 27 analysts implies -0.9% from the last close, and Ticker Nerd's factor model ranks Thermo Fisher Scientific, Inc. 84 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Thermo Fisher Scientific, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TMO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $560 to $800 over the next 12 months.
Thermo Fisher Scientific, Inc. returned +32.4% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Thermo Fisher Scientific Inc. is a global life sciences company that provides analytical instruments, laboratory products, specialty diagnostics, and biopharma services.
The most recent item we track (Benzinga, 15 Oct 2026): "Pfizer, Thermo Fisher Scientific And More: CNBC's ‘Final Trades'". On CNBC’s “Halftime Report Final Trades,” Stephen Weiss picked the U.S. 10 Year Treasury. The excerpt does not say that he selected Thermo Fisher Scientific.
Thermo Fisher Scientific Inc. is a global life sciences company that provides analytical instruments, laboratory products, specialty diagnostics, and biopharma services. Its portfolio supports scientific research, clinical testing, drug discovery, and pharmaceutical manufacturing through a broad range of instruments, reagents, consumables, software, and services. The company serves customers across pharmaceutical and biotechnology firms, hospitals, clinical diagnostic laboratories, universities, research institutions, and government agencies. Thermo Fisher Scientific Inc. operates through several business segments that address research, analysis, diagnostics, and laboratory workflow needs, making it an important supplier to healthcare, industrial, and scientific markets worldwide. Headquartered in Waltham, Massachusetts, Thermo Fisher Scientific Inc. is recognized for its role in enabling laboratory productivity and supporting the development, testing, and production of modern therapies and diagnostics.
CEO Mr. Marc N. Casper · 125,000 employees · United States · https://www.thermofisher.com
